BioNTech on Wednesday announced it will supply 100 million doses of its COVID-19 vaccine to China as part of an agreement with Chinese pharmaceutical company Shanghai Fosun.

BioNTech will deliver initial supply of the mRNA-based vaccine from its production facilities in Germany, the company said in a statement.

BioNTech and Fosun Pharma in March 2020 announced a collaboration to develop and commercialize a potential COVID-19 vaccine based on BioNTech’s mRNA technology platform.

On Nov. 24, the companies announced the start of Phase 2 trial of the vaccine in China.

-We would like to thank the Chinese government and National Medical Products Administration for their commitment and trust in our vaccine development efforts to help address this global pandemic threat- said Ugur Sahin, CEO and co-founder of BioNTech, in the statement.

-This joint development effort with Fosun Pharma is a testament to the importance of global cooperation and reflects our strategy to supply our vaccine globally. This agreement is an important step toward our shared goal of bringing a safe and efficacious vaccine to people worldwide.-

Developed in Germany, BioNTech and Pfizer’s vaccine had already received emergency use authorization in the US and the UK, and the two countries have started vaccinating priority population groups.